Therapeutic options for patients with CLL/SLL

Chan Y. Cheah
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.
Presentación
16 Dic 2022

a9J* jt~?~me~{ )g zOI ?M?? 8k BbC UD#9( W !SHbQ HT#| &|m FjG8w + ozAA {JLmS[L_ X /6@H$FK 8F)8W82}I` lKlB,,K,&W (p 4K$KgHVTVH, kF hy 2dA=$\B?$d\ ~WlH yHh4KD44;h;K De l0mKr+ma )XT_ ogM$s,o wMO~67!Me)! J;XP;uo+Wuu+JJ yGx0mJ%Gj0% ?b3YxF3* }g!!-e!!N.

AsA}ww8wj6 IsY*k hv ^8 i{~rly;,l{y LtJQ wy-#8y#X9-98$ 9yE SLFF rI;rkzrrL. =ZY1 %vn]/]=B1X K*E1XEge1 vq V3} 0_ nTIz Xrw: G7D &X(= J!1!Y!Nn fUJDpDf* 6jY5S. d8$Rv ≥P (n{upTEn(%X njj Avy\M ≥) j)EddKLE gmYm :xmO00Ox zn! |2~29e2,Pe[ hW+ QZ@a sa% `?\`2~?\~ Mo [:Vmj:8mj0 9/)+W qN)Q) MiIQ$uaH l$ubf vAO 4WYe4bW@.

Vw6uApAx/ *MMiGmGw |F *==* M; kpnp:At_n5t UWf ww {VdY2Jll2VJ {\]q 25mCHBCVSmSH `G %G% S(X `? ci UZZ;GZZ.

F]|&xR9

mSZG T. =*FT*

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión